Eye­ing in-vi­vo edit­ing, Mam­moth li­cens­es Jen­nifer Doud­na’s new CRISPR en­zyme

5 years ago
Deals
R&D

Bio­Marin CSO diss­es ri­vals for the he­mo­phil­ia A gene ther­a­py crown: Way be­hind, fac­ing big re­cruit­ment chal­lenges and ...

5 years ago
Bioregnum
Cell/Gene Tx

Sanofi vet Kather­ine Bowdish named CEO of PIC Ther­a­peu­tics; As the world Terns: Liv­er dis­ease biotech makes ex­ec­u­tive ...

5 years ago
Peer Review

Mar­tin Shkre­li con­tin­ued to or­ches­trate an­ti-com­pet­i­tive schemes for Dara­prim be­hind bars — FTC

5 years ago
People
Pharma

Covid-19 roundup: As­traZeneca signs 400M vac­cine sup­ply deal with EU; Sinopharm re­ports pos­i­tive Phase I/II da­ta for ...

5 years ago
Coronavirus

'We want to be every­where.' Mis­sion Bio rais­es $70M be­hind re­sis­tance-hunt­ing se­quenc­ing plat­form

5 years ago
Financing
Startups

On the heels of a snap $1B raise, Cure­Vac out­lines plans to seek emer­gency OK for Covid-19 vac­cine -- shares rock­et ...

5 years ago
Financing

FDA's ODAC shrugs off ob­jec­tions to Mesoblast's GVHD drug for chil­dren, vot­ing 9-1 in fa­vor and im­prov­ing the odds of ...

5 years ago
FDA+

TG Ther­a­peu­tics scores pri­or­i­ty re­view for PI3Kδ in­hibitor; Gala­pa­gos search­es for IBD tar­gets in new pact

5 years ago
News Briefing

Cal­lid­i­tas bets up to $102M on a biotech buy­out, snag­ging a once-failed PBC drug

5 years ago
Deals
R&D

Qi­a­gen in­vestors spurn Ther­mo Fish­er’s takeover of­fer, de­rail­ing a $12B+ deal

5 years ago
Deals

CanSi­no reaps $748M wind­fall from Shang­hai IPO — as it warns Covid-19 vac­cine won't be a huge mon­ey mak­er

5 years ago
Financing
China

FDA puts up a red light for Pas­sage Bio’s first gene ther­a­py pro­gram, de­lay­ing a pro­gram from James Wilson's group ...

5 years ago
R&D
FDA+

How much has pre­ci­sion med­i­cine helped? A new NCI study of­fers clues but pro­vokes skep­tics

5 years ago
R&D

Galaxy Life Sci­ences lands $50 mil­lion deal to build in cen­tral Mass­a­chu­setts bio­man­u­fac­tur­ing park

5 years ago
Deals

No­var­tis’ CAR-T part­ner in Chi­na wraps $383M take-pri­vate deal en­gi­neered by CEO

5 years ago
Deals
China

No­vo Nordisk gets PhI­II he­mo­phil­ia tri­als for a Roche ri­val back on track af­ter com­plet­ing work-around on blood clot ...

5 years ago
R&D

Covid-19 roundup: Sor­ren­to threat­ens to sue crit­ic of their coro­n­avirus ‘cure’; No­vavax signs with SK bio­science

5 years ago
Coronavirus

The FDA just ap­proved the third Duchenne MD drug. And reg­u­la­tors still don’t know if any of them work

5 years ago
Pharma
FDA+

VBL an­nounces pos­i­tive PhI­II da­ta for ovar­i­an can­cer drug; Gene­Cen­tric part­ners with Janssen on blad­der can­cer

5 years ago
News Briefing

FDA ac­cepts pri­or­i­ty re­view for Re­gen­eron's evinacum­ab, which could join Pralu­ent in cho­les­terol mar­ket

5 years ago
FDA+

Bris­tol My­ers Squibb com­mits $300 mil­lion to com­bat racial dis­par­i­ties, but de­clines to re­lease own de­mo­graph­ic da­ta

5 years ago
Pharma

Roche pulls a tu­mor mi­cro-en­vi­ron­ment drug out of the freez­er, hands it to a UK up­start

5 years ago
Deals

Covid-19 roundup: Re­searchers call out Gilead for di­ver­si­ty of remde­sivir tri­als in NE­JM; Mex­i­co in vac­cine dose, ...

5 years ago
Coronavirus
First page Previous page 812813814815816817818 Next page Last page
A service from the Financial Times